Elicera Therapeutics AB (ELIC) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.156x

Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has a cash flow conversion efficiency ratio of -0.156x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.74 Million ≈ $-509.90K USD) by net assets (Skr30.33 Million ≈ $3.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Elicera Therapeutics AB - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Elicera Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Elicera Therapeutics AB for a breakdown of total debt and financial obligations.

Elicera Therapeutics AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Elicera Therapeutics AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Emmbi Industries Limited NSE:EMMBI	0.023x
Inter Rock Minerals Inc V:IRO	0.238x
Union Plastic Public Company Limited BK:UP	-0.006x
Hands Corporation Ltd KO:143210	0.249x
Heng Huat Resources Group Bhd KLSE:0175	-0.020x
De.Mem Ltd AU:DEM	0.064x
GENOMTEC S.A. ZY -10 F:4VI	N/A
Eksons Corp Bhd KLSE:9016	0.006x

Annual Cash Flow Conversion Efficiency for Elicera Therapeutics AB (2017–2024)

The table below shows the annual cash flow conversion efficiency of Elicera Therapeutics AB from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Elicera Therapeutics AB worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr20.77 Million ≈ $2.24 Million	Skr-23.46 Million ≈ $-2.53 Million	-1.130x	-24.16%
2023-12-31	Skr16.40 Million ≈ $1.77 Million	Skr-14.92 Million ≈ $-1.61 Million	-0.910x	-248.18%
2022-12-31	Skr32.80 Million ≈ $3.53 Million	Skr-8.57 Million ≈ $-922.36K	-0.261x	+4.50%
2021-12-31	Skr52.24 Million ≈ $5.62 Million	Skr-14.29 Million ≈ $-1.54 Million	-0.274x	-209.39%
2020-12-31	Skr10.24 Million ≈ $1.10 Million	Skr-905.25K ≈ $-97.42K	-0.088x	+77.29%
2019-12-31	Skr614.10K ≈ $66.09K	Skr-239.16K ≈ $-25.74K	-0.389x	-31.11%
2018-12-31	Skr805.16K ≈ $86.65K	Skr-239.16K ≈ $-25.74K	-0.297x	-0.44%
2017-12-31	Skr808.69K ≈ $87.03K	Skr-239.16K ≈ $-25.74K	-0.296x	--

About Elicera Therapeutics AB

ST:ELIC Sweden Biotechnology

Market Cap

$17.45 Million

Skr162.11 Million SEK

Market Cap Rank

#25440 Global

#524 in Sweden

Share Price

Skr3.34

Change (1 day)

+5.70%

52-Week Range

Skr3.13 - Skr7.90

All Time High

Skr8.56